Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: Kingfisher who wrote (4660)	11/30/1999 11:13:00 AM
From: Kingfisher	Respond to of 4891

Most of us know that some 37-years ago eleven or so leading practitioners got together in Miami for a symposium on Reticulose. They related their experiences regarding the success they had in administering that drug to treat a number of virus infections but because their results were anecdotal, their findings and conclusions were summarily dismissed. Their efforts to honestly inform the public and government [FDA] officials was met with them being band from using the drug. We now have a situation where Dr. Hirschman has provided more anecdotal findings. Fortunately, these findings are backed by well logged scientific and statistical data concerning a resounding success in treating the most feared and devastating virus ever know to mankind, the HIV virus, which is blanketing every corner of the entire earth. These anecdotal findings are telling every AIDS patient who is on the AIDS cocktail — "Take Reticulose [substance R] with your cocktail or die". I feel confident that the medical and scientific community along with the FDA are extremely excited about and are not summarily dismissing Dr. Hirschman's recent findings but on the other hand the financial community seems to be doing so. This is not because of a lack in understand Dr. Hirschman's outstanding scientific findings but because ADVR is a penny stock which cannot or will not be supported by fund managers and which is subject to market maker manipulation. I am further confident that some how in the near future this lack of support of the ADVR stock will be dramatically reversed because of corrective actions that should be taken by ADVR management. Thus, I guess what is important at this juncture is to ensure that one has taken on a long-term position in the stock, or add to a long -term position, while there is time to do so at what appear to be very decent prices.

To: Kingfisher who wrote (4660)	11/30/1999 12:06:00 PM
From: Kingfisher	Read Replies (1) \| Respond to of 4891

Even though I am confident that the medical and scientific community is paying attention to Dr. Hirschman's research, it appears as though the AIDS advocates are not willing to fully support his findings even though these findings blatantly imply that PWAs must take substance R with their AIDS cocktails or they will die. I could be totally wrong, and I sincerely hope I am, but I have not seen or heard a word from Martin Delaney of the San Francisco-based AIDS patient advocacy group Project Inform, or David Gilden, editor of Treatment Issues, a news letter published by the Gay Mens Health Crisis of New York, that demonstrates support for Dr. Hirschman's recent anecdotal results. I hope there are good reasons for the silence on their part and that swallowing their pride is not getting in the way of their concerns for PWAs nor in openly or publicly supporting Dr. Hirschman work. If I am wrong in this opinion I would like to be corrected. If anyone has heard from these two AIDS advocates or any other advocates or AIDS organization that are openly supporting Dr. Hirschman's work, could you please post your findings.